Distalmotion, a medical technology company empowering access to the benefits of robotic surgery in outpatient sites of care, has announced the successful closing of its Series G financing round. The $150 million financing was led by Revival Healthcare Capital and included inside investor participation.
This new funding will be used primarily to accelerate US commercial adoption of Dexter, its soft tissue robotic surgery system, as well as to support ongoing clinical and product development initiatives.
A major focus of the US expansion continues to be the Ambulatory Surgery Center (ASC) market – one of the fastest-growing segments in surgical care, driven by the ongoing shift toward efficient, outpatient surgery.
“This funding marks another important milestone on our journey,” said Greg Roche, CEO of Distalmotion. “The continued commitment of our investors validates our vision to break down barriers to robotic access through simplified operations.
“As we enter our next phase of US market acceleration, ASCs represent a tremendous opportunity for Dexter. The ongoing support from our investors reaffirms our roadmap, our mission, and the value Dexter brings to minimally invasive surgery.”
In conjunction with the financing, Distalmotion has named Chas McKhann as executive chairman of the board of directors. With more than 25 years in the MedTech and life sciences industries, McKhann brings a wealth of experience in scaling medical device companies, commercial acceleration, and guiding organizations through strategic growth.
McKhann previously served as CEO of Apollo Endosurgery and then Silk Road Medical, two publicly traded medical device companies, where his leadership drove significant sales growth and ultimately resulted in successful exits. His appointment underscores Distalmotion’s commitment to establish a Dexter leadership position in ASCs.
“I am thrilled to join the Distalmotion team,” said McKhann. “Distalmotion has reimagined how robotic surgery can be adopted across care settings because Dexter delivers all the benefits of robotic surgery – dexterity, precision, and ergonomics – while also offering flexibility, efficiency, and value.
“With the recent FDA clearance in gynecology and release of Dexter product enhancements, the company is poised to accelerate adoption in the US and globally at this pivotal stage in its growth trajectory.”
Dexter has been successfully integrated into clinical practice across Europe and the US, with almost 3,000 patients treated. With strong clinical traction and continued investment, Distalmotion is positioned to empower more surgeons across sites of care to deliver the benefits of robotic surgery to their patients.
